MD Anderson and Nexo Therapeutics announced a multi-year collaboration that combines Nexo's discovery platform with MD Anderson's TRACTION capabilities to move new small-molecule cancer therapies toward the clinic.
The announcement emphasized the fit between Nexo’s CODON and INFINI-T capabilities and MD Anderson’s disease models, biomarker work and clinical insight. Under the agreement, Nexo retains program rights while MD Anderson is eligible for research support, milestones and royalties tied to future progress.
MD Anderson Cancer Center and Nexo Therapeutics announced a multi-year strategic collaboration that combines Nexo’s discovery platform with MD Anderson’s TRACTION translational research and development capabilities. The partners said they plan to work from target discovery through IND-enabling studies to move new small-molecule oncology programs forward more quickly.